Idogen’s newly appointed interim CEO Christina Herder took the opportunity to introduce herself and above all the company at the BioStock Investor Meeting. The company, which is developing tolerogenic cell therapies and is approaching a phase I/IIa study with the main candidate IDO8, has also begun the exercise period for warrants of series TO 5. This runs between 15 – 29 September.
See Idogen’s presentation below.The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.